TY - JOUR
T1 - Silymarin in the treatment of patients with primary sclerosing cholangitis
T2 - An open-label pilot study
AU - Angulo, Paul
AU - Jorgensen, Roberta A.
AU - Kowdley, Kris V.
AU - Lindor, Keith D.
N1 - Copyright:
Copyright 2008 Elsevier B.V., All rights reserved.
PY - 2008/6
Y1 - 2008/6
N2 - No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum alkaline phosphatase activity (1131 ± 216 vs. 861 ± 139, P = 0.007), and aspartate aminotransferase (AST) levels (116 ± 15 vs. 83 ± 11, P = 0.01) occurred with treatment. Serum bilirubin levels were not significantly affected by the treatment, while serum albumin and the Mayo risk score remained essentially unchanged. Overall, 34% of patients had a positive response to silymarin as defined by ≥50% improvement or normal status in liver tests. The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial.
AB - No effective medical therapy is available for patients with primary sclerosing cholangitis (PSC). We evaluated the safety and estimated the efficacy of silymarin in patients with PSC in a pilot study. Thirty patients with PSC were enrolled. Silymarin, 140 mg orally three times daily, was given for 1 year. A statistically significant improvement in serum alkaline phosphatase activity (1131 ± 216 vs. 861 ± 139, P = 0.007), and aspartate aminotransferase (AST) levels (116 ± 15 vs. 83 ± 11, P = 0.01) occurred with treatment. Serum bilirubin levels were not significantly affected by the treatment, while serum albumin and the Mayo risk score remained essentially unchanged. Overall, 34% of patients had a positive response to silymarin as defined by ≥50% improvement or normal status in liver tests. The results of this pilot study warrant further evaluation of silymarin in patients with PSC in a large-scale, controlled trial.
KW - Primary sclerosing cholangitis
KW - Silymarin
KW - Treatment
UR - http://www.scopus.com/inward/record.url?scp=43049118972&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=43049118972&partnerID=8YFLogxK
U2 - 10.1007/s10620-007-0052-6
DO - 10.1007/s10620-007-0052-6
M3 - Article
C2 - 17940903
AN - SCOPUS:43049118972
VL - 53
SP - 1716
EP - 1720
JO - American Journal of Digestive Diseases
JF - American Journal of Digestive Diseases
SN - 0002-9211
IS - 6
ER -